Biodesix Announces Two Presentations on Lung Cancer Treatmen

New data highlights two novel proteomic tests that support treatment decision making in patients with non-small cell lung cancer :



Expanded analysis of the VeriStrat® host immune classifier’s...

Related Keywords

, Wallace Akerley , Nasdaq , Langone Health , Lung Cancer Disease Center , Research For Cardiothoracic Surgery , Perlmutter Cancer Institute , Biodesix Inc , University Of Utah , Excellence At Huntsman Cancer Institute , Lung Cancer Center , International Association , Lung Cancer , Lung Conference , Clinical Effectiveness Assessment , Host Immune Classifier Cold , Veristrat Poor , Real World Efficacy , Serum Proteomics , Huntsman Cancer Institute , Metastatic Non Small Cell Lung Cancer , Exhibit Hall , Enhanced Assessment , Recurrence Risk , Combined Adenocarcinoma Grading System , Serum Proteomic Testing , Harvey Pass , Vice Chair , Cardiothoracic Surgery , Cancer Center , Early Stage Non Small Cell Lung Cancer , Changing Paradigms , Artificial Intelligence , Private Securities Litigation Reform Act , Risk Factors , Markets ,